HUTCHMED (China) (HCM) EBT Margin (2015 - 2021)

HUTCHMED (China) (HCM) posted quarterly EBT Margin of 172.21% for Q4 2021, down 123.26% quarter-over-quarter from 77.13% in Q1 2021.

HUTCHMED (China) (HCM) EBT Margin (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has reported EBT Margin for 6 consecutive years, with 172.21% the latest figure, recorded in Q4 2021.

In Q4 2021, EBT Margin changed N/A year-over-year to 172.21%; the TTM figure through Dec 2021 stood at 117.03% (changed N/A YoY), while the FY2025 annual figure was 90.92%, up 9854.0% from the prior year.
EBT Margin fell to 172.21% in Q4 2021 per HCM's latest filing, from 77.13% in the prior quarter.
Across five years, EBT Margin topped out at 149.17% in Q2 2018 and bottomed at 206.3% in Q2 2019.
Historically, EBT Margin has averaged 41.99% across 4 years, with a median of 65.16% in 2019.
Annual changes were most pronounced in 2019 — EBT Margin sank 35547 bps — and 2020, when it surged 12430 bps.
HUTCHMED (China)'s EBT Margin stood at 43.42% in 2018, then plunged by 266 bps to 72.11% in 2019, then fell by 14 bps to 82.0% in 2020, then tumbled by 110 bps to 172.21% in 2021.
Business Quant data shows HCM's EBT Margin at 172.21% in Q4 2021, 77.13% in Q1 2021, and 82.0% in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-10.99%
3	Zoetis	31.53 Bn	29.85 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn	13.34%
5	United Therapeutics	22.13 Bn	19.47 Bn	683.80 Mn	47.58%
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	-1.70%
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn	16.91%
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn	4.09%
9	Dr Reddys Laboratories	10.13 Bn	9.97 Bn	-	-
10	HUTCHMED (China)	2.17 Bn	2.17 Bn	-	-

Download Data